Abeona Therapeutics Inc vs Rush Street Interactive Inc — how do they compare? Abeona Therapeutics Inc trades at $6.19 (market cap $425.47M), while Rush Street Interactive Inc trades at $24.45 (market cap $2.81B). The key difference: Rush Street Interactive Inc is far larger — about 6.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Rush Street Interactive Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | RSI | |
|---|---|---|
Market Cap | $425.47M | $2.81B |
Sector | Health | Technology |
52-Week High | $7.46 | $34.52 |
52-Week Low | $4.17 | $15.89 |
Enterprise Value | $280.37M | $2.47B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
Rush Street Interactive (RSI) trades at $24.28, down 1.78% over 24 hours, with a bearish technical signal from moving averages despite bullish oscillators. The company reported record Q2 2026 revenue of $393.8 million, up 46% year-over-year, and raised full-year guidance. Financials show strong revenue growth but thin net margins of 2.33%, with elevated valuation ratios like a P/E of 81.13. Analyst consensus is strongly bullish with a $34.75 price target.
The outlook is positive due to robust revenue growth and expansion in online casino and sports betting markets, but risks include high valuation sensitivity and competitive pressures. Institutional buying by firms like Dimensional Fund Advisors supports sentiment, though insider selling post-rally warrants monitoring. The stock offers growth potential if execution continues, but investors should weigh margin pressures against expansion prospects.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →